RWE(Real World Evidence) 솔루션 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)
Global Real World Evidence Solutions Market Size, Share, Trends & Growth Analysis Report 2026-2034
상품코드:1936748
리서치사:Value Market Research
발행일:2026년 02월
페이지 정보:영문 166 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
RWE(Real World Evidence) 솔루션 시장 규모는 2025년 36억 7,000만 달러에서 2034년에는 79억 3,000만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 8.93%로 성장할 전망입니다.
세계 RWE(Real World Evidence) 솔루션 시장은 의료 의사결정에 있어 데이터 기반 인사이트에 대한 수요 증가로 인해 큰 폭의 성장이 예상됩니다. RWE는 환자의 건강 상태와 의료 제공에 대한 정보를 포함한 실제 데이터 분석을 통해 얻은 임상적 증거를 말합니다. 제약사, 지불자, 규제기관 등 의료 생태계 이해관계자들이 치료 효과와 안전성에 대한 이해도가 높아짐에 따라 RWE 솔루션 도입이 크게 증가할 것으로 예상됩니다. 이러한 추세는 가치 기반 의료에 대한 관심 증가와 상환 결정의 근거가 되는 증거에 대한 필요성에 의해 더욱 강화되고 있습니다.
또한, 데이터 분석 기술과 기술의 발전은 RWE 솔루션의 영역을 변화시킬 것으로 예상됩니다. 빅데이터, 머신러닝, 인공지능의 통합으로 방대한 실제 데이터 분석 능력이 향상되어 임상 진료와 정책 수립에 도움이 되는 실용적인 인사이트를 제공하고 있습니다. 또한, 전자건강기록 및 환자 등록 시스템의 보급으로 고품질 데이터 수집이 용이해짐에 따라 RWE 솔루션에 대한 수요는 더욱 증가하고 있습니다. 의료 기관이 임상 및 상업적 전략을 뒷받침하는 실제 증거의 가치를 인식함에 따라, 이러한 요구를 충족시키는 혁신적인 솔루션이 시장에 급증할 것으로 예상됩니다.
또한, 환자 참여에 대한 관심 증가와 환자 보고 결과의 중요성이 RWE 솔루션 시장의 미래를 좌우할 것으로 예상됩니다. 환자가 자신의 의료 결정에 깊이 관여하게 되면서 환자의 경험과 결과를 파악할 수 있는 솔루션의 필요성이 점점 더 중요해지고 있습니다. 환자의 관점을 통합한 RWE 솔루션은 치료 효과에 대한 보다 종합적인 이해를 제공하고, 궁극적으로 환자 치료의 개선으로 이어집니다. 데이터 제공자, 의료 기관, 규제 당국 간의 협력은 이러한 발전을 촉진하고 RWE 솔루션 시장이 근거 기반 의료의 최전선에 서는 데 필수적입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 RWE(Real World Evidence) 솔루션 시장 : 구성요소별
제5장 세계의 RWE(Real World Evidence) 솔루션 시장 : 용도별
제6장 세계의 RWE(Real World Evidence) 솔루션 시장 : 최종사용별
제7장 세계의 RWE(Real World Evidence) 솔루션 시장 : 치료 분야별
제8장 세계의 RWE(Real World Evidence) 솔루션 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM
영문 목차
영문목차
The Real World Evidence Solutions Market size is expected to reach USD 7.93 Billion in 2034 from USD 3.67 Billion (2025) growing at a CAGR of 8.93% during 2026-2034.
The global real-world evidence (RWE) solutions market is set to witness substantial growth, driven by the increasing demand for data-driven insights in healthcare decision-making. RWE refers to the clinical evidence derived from the analysis of real-world data, which includes information on patient health status and the delivery of healthcare. As stakeholders in the healthcare ecosystem, including pharmaceutical companies, payers, and regulatory agencies, seek to enhance the understanding of treatment effectiveness and safety, the adoption of RWE solutions is expected to rise significantly. This trend is further supported by the growing emphasis on value-based care and the need for evidence to inform reimbursement decisions.
Moreover, advancements in data analytics and technology are anticipated to transform the RWE solutions landscape. The integration of big data, machine learning, and artificial intelligence is enhancing the ability to analyze vast amounts of real-world data, providing actionable insights that can inform clinical practice and policy. Additionally, the increasing availability of electronic health records and patient registries is facilitating the collection of high-quality data, further driving the demand for RWE solutions. As healthcare organizations increasingly recognize the value of real-world evidence in supporting clinical and commercial strategies, the market is likely to witness a surge in innovative solutions that cater to these needs.
In addition, the growing focus on patient engagement and the importance of patient-reported outcomes are expected to shape the future of the RWE solutions market. As patients become more involved in their healthcare decisions, the need for solutions that capture their experiences and outcomes is becoming increasingly important. RWE solutions that incorporate patient perspectives can provide a more comprehensive understanding of treatment impact, ultimately leading to improved patient care. Collaborative efforts between data providers, healthcare organizations, and regulatory bodies will be essential in driving these advancements, ensuring that the RWE solutions market remains at the forefront of evidence-based healthcare.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Component
Services
Data Sets
By Application
Drug Development & Approvals
Medical Device Development & Approvals
Reimbursement/Coverage and Regulatory Decision Making
Post Market Safety & Adverse Events Monitoring
By End-use
Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
Healthcare Payers
Healthcare Providers
Others
By Therapeutic Area
Oncology
Cardiology
Neurology
Diabetes
Psychiatry
Respiratory
Others
COMPANIES PROFILED
IQVIA Inc, IBM, PPD Inc acquired by Thermo Fisher Scientific Inc, Parexel International MA Corporation, PerkinElmer Inc, ICON plc, Oracle, Syneos Health, Cegedim Health Data, Medpace
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET: BY COMPONENT 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Component
4.2. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Data Sets Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET: BY APPLICATION 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Application
5.2. Drug Development & Approvals Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Medical Device Development & Approvals Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Reimbursement/Coverage and Regulatory Decision Making Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Post Market Safety & Adverse Events Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET: BY END-USE 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast End-use
6.2. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Healthcare Payers Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Healthcare Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)
7.1. Market Analysis, Insights and Forecast Therapeutic Area
7.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.6. Psychiatry Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.7. Respiratory Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL REAL WORLD EVIDENCE SOLUTIONS MARKET: BY REGION 2022-2034(USD MN)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.2.1 By Component
8.2.2 By Application
8.2.3 By End-use
8.2.4 By Therapeutic Area
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.3.1 By Component
8.3.2 By Application
8.3.3 By End-use
8.3.4 By Therapeutic Area
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.4.1 By Component
8.4.2 By Application
8.4.3 By End-use
8.4.4 By Therapeutic Area
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.5.1 By Component
8.5.2 By Application
8.5.3 By End-use
8.5.4 By Therapeutic Area
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.6.1 By Component
8.6.2 By Application
8.6.3 By End-use
8.6.4 By Therapeutic Area
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL REAL WORLD EVIDENCE SOLUTIONS INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Company Profiles
10.2.1 IQVIA Inc
10.2.2 IBM
10.2.3 PPD Inc. (Acquired By Thermo Fisher Scientific Inc.)
